Literature DB >> 27107797

Microglial phenotypes in Parkinson's disease and animal models of the disease.

Valerie Joers1, Malú G Tansey2, Giovanna Mulas3, Anna R Carta4.   

Abstract

Over the last decade the important concept has emerged that microglia, similar to other tissue macrophages, assume different phenotypes and serve several effector functions, generating the theory that activated microglia can be organized by their pro-inflammatory or anti-inflammatory and repairing functions. Importantly, microglia exist in a heterogenous population and their phenotypes are not permanently polarized into two categories; they exist along a continuum where they acquire different profiles based on their local environment. In Parkinson's disease (PD), neuroinflammation and microglia activation are considered neuropathological hallmarks, however their precise role in relation to disease progression is not clear, yet represent a critical challenge in the search of disease-modifying strategies. This review will critically address current knowledge on the activation states of microglia as well as microglial phenotypes found in PD and in animal models of PD, focusing on the expression of surface molecules as well as pro-inflammatory and anti-inflammatory cytokine production during the disease process. While human studies have reported an elevation of both pro- or anti-inflammatory markers in the serum and CSF of PD patients, animal models have provided insights on dynamic changes of microglia phenotypes in relation to disease progression especially prior to the development of motor deficits. We also review recent evidence of malfunction at multiple steps of NFκB signaling that may have a causal interrelationship with pathological microglia activation in animal models of PD. Finally, we discuss the immune-modifying strategies that have been explored regarding mechanisms of chronic microglial activation.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immune; Microglia; Neurodegeneration; Neuroinflammation; Neuroprotection; Parkinson’s

Mesh:

Year:  2016        PMID: 27107797      PMCID: PMC5073045          DOI: 10.1016/j.pneurobio.2016.04.006

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  224 in total

Review 1.  Microglia phenotype diversity.

Authors:  M Olah; K Biber; J Vinet; H W G M Boddeke
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-02       Impact factor: 4.388

2.  Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta.

Authors:  H J Jyothi; D J Vidyadhara; Anita Mahadevan; Mariamma Philip; Suresh Kumar Parmar; S Gowri Manohari; S K Shankar; Trichur R Raju; Phalguni Anand Alladi
Journal:  Neurobiol Aging       Date:  2015-08-31       Impact factor: 4.673

Review 3.  Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology.

Authors:  J J M Hoozemans; R Veerhuis; J M Rozemuller; P Eikelenboom
Journal:  Int J Dev Neurosci       Date:  2005-12-27       Impact factor: 2.457

4.  Biochemical and functional characterization of three activated macrophage populations.

Authors:  Justin P Edwards; Xia Zhang; Kenneth A Frauwirth; David M Mosser
Journal:  J Leukoc Biol       Date:  2006-08-11       Impact factor: 4.962

5.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

6.  Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease.

Authors:  M Mogi; M Harada; T Kondo; H Narabayashi; P Riederer; T Nagatsu
Journal:  Neurosci Lett       Date:  1995-06-30       Impact factor: 3.046

7.  Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease.

Authors:  Manuel Rodriguez; Lydia Alvarez-Erviti; Francisco J Blesa; Maria C Rodríguez-Oroz; Ainhoa Arina; Ignacio Melero; Luís Isaac Ramos; Jose A Obeso
Journal:  Neurobiol Dis       Date:  2007-08-07       Impact factor: 5.996

8.  A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results.

Authors: 
Journal:  Clin Neuropharmacol       Date:  2008 May-Jun       Impact factor: 1.592

9.  Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease.

Authors:  Heather L Martin; Ross B Mounsey; Sarah Mustafa; Kinnari Sathe; Peter Teismann
Journal:  Exp Neurol       Date:  2012-03-07       Impact factor: 5.330

10.  MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration.

Authors:  Carolina Cebrián; Fabio A Zucca; Pierluigi Mauri; Julius A Steinbeck; Lorenz Studer; Clemens R Scherzer; Ellen Kanter; Sadna Budhu; Jonathan Mandelbaum; Jean P Vonsattel; Luigi Zecca; John D Loike; David Sulzer
Journal:  Nat Commun       Date:  2014-04-16       Impact factor: 14.919

View more
  79 in total

1.  TSPO Modulates IL-4-Induced Microglia/Macrophage M2 Polarization via PPAR-γ Pathway.

Authors:  Dandan Zhou; Lei Ji; Youguo Chen
Journal:  J Mol Neurosci       Date:  2019-12-26       Impact factor: 3.444

Review 2.  Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms.

Authors:  Arthi Kanthasamy; Huajun Jin; Adhithiya Charli; Anantharam Vellareddy; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 3.  Outdoor Ambient Air Pollution and Neurodegenerative Diseases: the Neuroinflammation Hypothesis.

Authors:  Richard L Jayaraj; Eric A Rodriguez; Yi Wang; Michelle L Block
Journal:  Curr Environ Health Rep       Date:  2017-06

Review 4.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

5.  RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.

Authors:  Katelin E Ahlers-Dannen; Mackenzie M Spicer; Rory A Fisher
Journal:  Mol Pharmacol       Date:  2020-02-03       Impact factor: 4.436

6.  Intragastric Administration of Casein Leads to Nigrostriatal Disease Progressed Accompanied with Persistent Nigrostriatal-Intestinal Inflammation Activited and Intestinal Microbiota-Metabolic Disorders Induced in MPTP Mouse Model of Parkinson's Disease.

Authors:  Xinrong Liu; Shuya Liu; Yong Tang; Zhengjia Pu; Hong Xiao; Jieying Gao; Qi Yin; Yan Jia; Qunhua Bai
Journal:  Neurochem Res       Date:  2021-03-15       Impact factor: 3.996

Review 7.  Implication of Neuronal Versus Microglial P2X4 Receptors in Central Nervous System Disorders.

Authors:  Alexia Duveau; Eléonore Bertin; Eric Boué-Grabot
Journal:  Neurosci Bull       Date:  2020-09-05       Impact factor: 5.203

8.  Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.

Authors:  Sara Hernando; Enara Herran; Joana Figueiro-Silva; José Luis Pedraz; Manoli Igartua; Eva Carro; Rosa Maria Hernandez
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

Review 9.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

10.  TREM2 deficiency aggravates α-synuclein-induced neurodegeneration and neuroinflammation in Parkinson's disease models.

Authors:  Ying Guo; Xinbing Wei; Hua Yan; Yue Qin; Shaoqi Yan; Jia Liu; Yong Zhao; Fan Jiang; Haiyan Lou
Journal:  FASEB J       Date:  2019-08-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.